Charles River Laboratories International, Inc. (CRL) Insider Trading

Last 12 months

Insiders bought $7k and sold $42.9M on the open market.

93% of the selling was scheduled in advance under 10b5-1 plans. SVP, Finance and CAO Michael Gunnar Knell sold $1.73M on Aug 6, 36% of their stake, outside a plan.

Net open-market

−$42.9M

2 buys · 11 sales

Under a 10b5-1 plan

93%

of the value sold

Insiders who bought / sold

2 / 6

executives and directors

Last open-market buy

Sep 2026

Sep 30, 2026

Get an email when CRL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 5	Shannon M Parisotto CEVP, Disc & Safety Assessment	Sold10b5-1 plan	981	$308.44	$303k	2.2%	Form 4
Sep 30	Glenn Coleman EVP & Chief Financial Officer	Bought	10	$297.43	$3k	<0.1%	Form 4
Aug 25	James C Foster Director	Sold10b5-1 plan	33,561	$300.00	$10.1M	13%	Form 4
Aug 19	Shannon M Parisotto CEVP, Disc & Safety Assessment	Sold10b5-1 plan	2,039	$294.12	$600k	4.5%	Form 4
Aug 18	Nancy C Andrews Director	SoldNo plan	573	$285.24	$163k	9.6%	Form 4
Aug 11	Birgit Girshick Chief Executive Officer	Sold10b5-1 plan	6,500	$279.90	$1.82M	7.5%	Form 4
Aug 11	Shannon M Parisotto CEVP, Disc & Safety Assessment	Sold10b5-1 plan	3,714	$279.66	$1.04M	8.0%	Form 4
Aug 10	James C Foster Director	Sold10b5-1 plan	28,733	$275.00	$7.9M	11%	Form 4
Aug 6	Michael Gunnar Knell SVP, Finance and CAO	SoldNo plan 9 parts	6,645	$260.38 average	$1.73M	36%	Form 4
Aug 6	Victoria L Creamer EVP & Chief People Officer	SoldNo plan	4,179	$259.16	$1.08M	12%	Form 4
Aug 5	Shannon M Parisotto CEVP, Disc & Safety Assessment	Sold10b5-1 plan	5,046	$263.00	$1.33M	11%	Form 4
Jun 29	James C Foster Director	Sold10b5-1 plan	75,000	$225.00	$16.9M	24%	Form 4
Mar 3	Joseph W Laplume EVP, Corp Strategy & Develop	Bought	25	$174.54	$4k	<0.1%	Form 4
Aug 22, 2025	Joseph W Laplume EVP, Corp Strategy & Develop	SoldNo plan	400	$163.72	$65k	1.7%	Form 4
Aug 18, 2025	Joseph W Laplume EVP, Corp Strategy & Develop	SoldNo plan	800	$157.60	$126k	3.2%	Form 4
Aug 7, 2025	Joseph W Laplume EVP, Corp Strategy & Develop	SoldNo plan	400	$150.04	$60k	1.6%	Form 4
May 15, 2025	George Massaro Director	Sold10b5-1 plan 3 parts	140	$137.57 average	$19k	2.4%	Form 4
May 14, 2025	George Massaro Director	Sold10b5-1 plan 5 parts	140	$140.74 average	$20k	2.4%	Form 4
May 13, 2025	Joseph W Laplume EVP, Corp Strategy & Develop	SoldNo plan	500	$145.41	$73k	2.5%	Form 4
Feb 20, 2025	James C Foster Chairman, President and CEO	Bought	6,075	$165.01	$1M	2.5%	Form 4
Feb 20, 2025	Birgit Girshick Corporate Executive VP & COO	Bought	1,514	$164.63	$249k	2.8%	Form 4
Feb 20, 2025	Joseph W Laplume EVP, Corp Strategy & Develop	SoldNo plan	4,400	$162.50	$715k	18%	Form 4
Nov 7, 2024	Richard F Wallman Director	SoldNo plan 3 parts	7,621	$216.17 average	$1.65M	38%	Form 4

Oct 510b5-1 plan
Shannon M Parisotto
CEVP, Disc & Safety Assessment · sold 981 at $308.44
$303k
2.2% of stake
Sep 30
Glenn Coleman
EVP & Chief Financial Officer · bought 10 at $297.43
$3k
<0.1% of stake
Aug 2510b5-1 plan
James C Foster
Director · sold 33,561 at $300.00
$10.1M
13% of stake
Aug 1910b5-1 plan
Shannon M Parisotto
CEVP, Disc & Safety Assessment · sold 2,039 at $294.12
$600k
4.5% of stake
Aug 18No plan
Nancy C Andrews
Director · sold 573 at $285.24
$163k
9.6% of stake
Aug 1110b5-1 plan
Birgit Girshick
Chief Executive Officer · sold 6,500 at $279.90
$1.82M
7.5% of stake
Aug 1110b5-1 plan
Shannon M Parisotto
CEVP, Disc & Safety Assessment · sold 3,714 at $279.66
$1.04M
8.0% of stake
Aug 1010b5-1 plan
James C Foster
Director · sold 28,733 at $275.00
$7.9M
11% of stake
Aug 6No plan
Michael Gunnar Knell
SVP, Finance and CAO · sold 6,645 at avg $260.38
$1.73M
36% of stake
Aug 6No plan
Victoria L Creamer
EVP & Chief People Officer · sold 4,179 at $259.16
$1.08M
12% of stake
Aug 510b5-1 plan
Shannon M Parisotto
CEVP, Disc & Safety Assessment · sold 5,046 at $263.00
$1.33M
11% of stake
Jun 2910b5-1 plan
James C Foster
Director · sold 75,000 at $225.00
$16.9M
24% of stake
Mar 3
Joseph W Laplume
EVP, Corp Strategy & Develop · bought 25 at $174.54
$4k
<0.1% of stake
Aug 22, 2025No plan
Joseph W Laplume
EVP, Corp Strategy & Develop · sold 400 at $163.72
$65k
1.7% of stake
Aug 18, 2025No plan
Joseph W Laplume
EVP, Corp Strategy & Develop · sold 800 at $157.60
$126k
3.2% of stake
Aug 7, 2025No plan
Joseph W Laplume
EVP, Corp Strategy & Develop · sold 400 at $150.04
$60k
1.6% of stake
May 15, 202510b5-1 plan
George Massaro
Director · sold 140 at avg $137.57
$19k
2.4% of stake
May 14, 202510b5-1 plan
George Massaro
Director · sold 140 at avg $140.74
$20k
2.4% of stake
May 13, 2025No plan
Joseph W Laplume
EVP, Corp Strategy & Develop · sold 500 at $145.41
$73k
2.5% of stake
Feb 20, 2025
James C Foster
Chairman, President and CEO · bought 6,075 at $165.01
$1M
2.5% of stake
Feb 20, 2025
Birgit Girshick
Corporate Executive VP & COO · bought 1,514 at $164.63
$249k
2.8% of stake
Feb 20, 2025No plan
Joseph W Laplume
EVP, Corp Strategy & Develop · sold 4,400 at $162.50
$715k
18% of stake
Nov 7, 2024No plan
Richard F Wallman
Director · sold 7,621 at avg $216.17
$1.65M
38% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CRL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Commercial Physical & Biological Research

MEDPMedpace Holdings Inc.

INCYIncyte Corporation

NOTVInotiv Inc.

IQVIQVIA Holdings Inc.

ULSUl Solutions Inc.

NEONeoGenomics Inc.

FCNFti Consulting Inc.

ASTHAstrana Health Inc.

Spot a number that looks wrong? Check it in CRL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CRL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.